TRVI

Trevi Therapeutics
TRVI

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
$1.42B
EV
$1.22B
Shares Outstanding
153.83M
Beta
0.84
Industry
Biotechnology

Wall Street View

Analyst Rating
BUY
Analyst Target Price
Number of Analysts
10
P/E 2025E
-
P/Revenue 2025E
-

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Trevi Therapeutics, Inc.

gainify
TRVI

Trevi Therapeutics, Inc.

TRVI

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting ...

Sector

Healthcare

Industry

Biotechnology

CEO

Good, Jennifer

Employees

33

IPO Date

2019-05-07

Headquarters

195 Church Street, 16th Floor, New Haven, Connecticut, 06510, United States

gainifypowered-by-sp
Socials
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on TrustpilotFollow us on YouTubeFind us on Google Maps

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2025 Gainify. All rights reserved.